Hanall Biopharma Co Ltd
KRX:009420
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24 250
56 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Hanall Biopharma Co Ltd's latest stock split occurred on May 24, 2006
The company executed a 4981-for-4732 stock split, meaning that for every 4732 shares held, investors received 4981 new shares.
The adjusted shares began trading on May 24, 2006. This was Hanall Biopharma Co Ltd's 5th stock split, following the previous one in May 3, 2006.
Hanall Biopharma Co Ltd
Glance View
Hanall Biopharma Co., Ltd., a Seoul-based pharmaceutical entity, has been navigating the competitive seas of the global health industry since 1973. Driven by a mission to address unmet medical needs, the company has positioned itself at the forefront of innovative drug development and biosimilars. Hanall's spotlight in recent years has been on its dedication to improving the lives of patients suffering from autoimmune and rare diseases. By focusing on cutting-edge solutions, the firm has garnered attention through its proprietary products and partnerships, such as its notable alliance with Harbour BioMed. This partnership has been pivotal in propelling their flagship drug candidates through the complex corridors of clinical trials and regulatory approvals. Central to Hanall Biopharma's business model is a dual strategy: developing novel therapeutics and capitalizing on biosimilar drugs. The company invests significantly in research and development, orchestrating a pipeline that balances groundbreaking therapies with the more predictable revenue streams of biosimilars. These biosimilars, essentially comparable versions of existing biologic drugs, allow Hanall to leverage lower development costs while addressing market demands for more affordable healthcare solutions. With revenues flowing from successful collaborations and sales of active pharmaceuticals, Hanall continues to chart a course through the diverse challenges of biopharmaceutical innovation and market competition.
LNNTF
LTSRF
AMCR
SURYY
ACET